Jeff Yass’s Centessa Pharmaceuticals CNTA Stock Holding History

Jeff Yass’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-118,800	Closed	-$4.72M	–	13513
2026 Q1	$4.72M	Sell	118,800 -41,700	-26%	-$1.07M	﹤0.01%	4336
2025 Q4	$4.01M	Sell	160,500 -269,800	-63%	-$6.83M	﹤0.01%	4376
2025 Q3	$10.4M	Buy	430,300 +238,200	+124%	+$4.23M	﹤0.01%	2988
2025 Q2	$2.52M	Buy	192,100 +112,800	+142%	+$1.43M	﹤0.01%	5307
2025 Q1	$1.14M	Buy	+79,300	New	+$1.3M	﹤0.01%	6920
2024 Q1	–	Sell	-11,200	Closed	-$89.2K	–	12306
2023 Q4	$89.2K	Sell	11,200 -7,300	-39%	-$48.9K	﹤0.01%	11411
2023 Q3	$120K	Buy	+18,500	New	+$127K	﹤0.01%	10774

Jeff Yass's CNTA Position: Q2 2026 in Review

Jeff Yass sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 17,737 shares — an estimated $705K sold.

Jeff Yass first reported a position in CNTA in Q1 2023 and held it in 6 quarters. The position peaked at $12.9M in Q1 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Jeff Yass reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 17,737 Centessa Pharmaceuticals shares in Q2 2026, an estimated $705K.
Jeff Yass first reported a position in Centessa Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Jeff Yass's Centessa Pharmaceuticals position peaked at $12.9M in Q1 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.